tiprankstipranks
Trending News
More News >

CollPlant Secures European Patent for Collagen-Based Formulations

Story Highlights
  • CollPlant Biotechnologies secured a European patent for its collagen-based formulations.
  • The patent strengthens CollPlant’s position in the aesthetic and reconstructive markets.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
CollPlant Secures European Patent for Collagen-Based Formulations

Confident Investing Starts Here:

The latest update is out from Collplant Holdings ( (CLGN) ).

On June 4, 2025, CollPlant Biotechnologies announced that it secured a European patent allowance for its collagen-based formulations used in soft tissue fillers and implants. This patent, effective until 2041, is a strategic move to strengthen CollPlant’s position in the growing markets for aesthetic and reconstructive procedures, with the injectable soft-tissue fillers market estimated at over $6 billion and the breast implants market at over $3 billion. The patent enhances CollPlant’s competitive edge by protecting its proprietary technology, particularly in Europe, a key target market.

The most recent analyst rating on (CLGN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

Spark’s Take on CLGN Stock

According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.

The overall score of 48 reflects significant financial challenges, marked by drastic revenue and cash flow declines. While technical analysis provides some positive signals, the valuation remains poor due to negative earnings. Despite promising advancements in preclinical programs and a stable cash runway, the financial outlook remains concerning.

To see Spark’s full report on CLGN stock, click here.

More about Collplant Holdings

CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen). The company operates in the fields of tissue repair, aesthetics, and organ manufacturing, with a strong emphasis on 3D bioprinting of tissues and organs.

Average Trading Volume: 66,626

Technical Sentiment Signal: Sell

Current Market Cap: $26.12M

For an in-depth examination of CLGN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App